Pneumagen

Executive Summary

Pneumagen is a clinical-stage biotech company headquartered in St Andrews, UK, dedicated to transforming prevention and treatment of viral respiratory tract infections. Its lead candidate, Neumifil, is a broad-spectrum intranasal antiviral designed to protect at-risk patients, such as those with chronic lung diseases, by preventing virally induced exacerbations. Neumifil targets a conserved region of the viral fusion protein, offering potential activity against multiple respiratory viruses including influenza, RSV, and coronaviruses. The company is currently advancing Neumifil through Phase 2 clinical trials, with a focus on demonstrating efficacy in reducing viral load and symptom severity in high-risk populations. Pneumagen's approach addresses a significant unmet medical need, as current options for broad-spectrum respiratory antiviral prevention are limited. The company has raised venture capital funding and is positioned for potential partnership or further financing as it progresses toward pivotal trials.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 topline data readout for Neumifil in prevention of viral respiratory infections60% success
• 2026Partnership or licensing deal with a larger pharma company for Neumifil development and commercialization40% success
• H2 2026Series B or Series C financing round to fund Phase 2b/3 trials70% success